



ASX and Media Release

## **Viralytics to Present New CAVATAK® Clinical Data at American Association for Cancer Research Annual Meeting 2017**

---

**2 March 2017, Sydney, Australia:** [Viralytics Limited](#) (ASX: VLA, OTC: VRACY) today announced that the company will present new clinical data from three combination studies of CAVATAK®, its novel investigational cancer immunotherapy, and checkpoint inhibitor drugs at the [American Association for Cancer Research \(AACR\) Annual Meeting 2017](#), which will be held in Washington DC from April 1 to 5. Details of the two podium presentations in a clinical trials plenary session and one poster presentation follow.

***The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment (Abstract CT114)***

- Session Title: Novel Immuno-Oncology Agent Clinical Trials
- Session Time: Tuesday Apr 4, 2017 10:30 AM - 12:45 PM
- Location: Ballroom C, Level 3, Washington Convention Center
- Presenter: Brendan Curti, MD, Director, Biotherapy Program, Earl A Chiles Research Institute at the Providence Cancer Center, Portland, Oregon.

The podium presentation will report preliminary data from the phase 1b MITCI (Melanoma Intra-Tumoral CAVATAK and Ipilimumab) study designed to evaluate the tolerability and anti-cancer activity of intralesionally injected CAVATAK, a proprietary cold virus that preferentially infects and attacks cancer cells, in combination with the systemic administration of the checkpoint inhibitor drug YERVOY®<sup>1</sup> (ipilimumab) in patients with unresectable melanoma.

The text of the abstract will be posted online on the [AACR meeting](#) and the Viralytics websites from 4:30 p.m. Eastern US time on Friday, March 31 (Saturday April 1 at 7.30am Sydney time). The slide deck will be available on the [AACR meeting](#) and the Viralytics websites at the date and time of the presentation.

***Phase 1b KEYNOTE-200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients (Abstract CT115)***

- Session Title: Novel Immuno-Oncology Agent Clinical Trials
- Session Time: Tuesday Apr 4, 2017 10:30 AM - 12:45 PM
- Location: Ballroom C, Level 3, Washington Convention Center

---

<sup>1</sup> YERVOY® is a trademark of the Bristol-Myers Squibb company



- Presenter: Charles Rudin, MD, PhD, Chief of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York

The podium presentation will report on progress in the KEYNOTE-200 study assessing the anti-cancer activity of the combination of intravenously delivered CAVATAK, and systemically administered KEYTRUDA<sup>®2</sup>, a checkpoint inhibitor drug, in patients with non-small cell lung or metastatic bladder cancer.

The text of the abstract will be posted online on the [AACR meeting](#) and the Viralytics websites from 4:30 p.m. Eastern US time on Friday, March 31 (Saturday April 1 at 7.30am Sydney time). The slide deck will be available on the [AACR meeting](#) and the Viralytics websites at the date and time of the presentation.

***Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial (Abstract CT026)***

- Poster Session: Phase I Clinical Trials in Progress
- Monday April 3, 2017, 8:00 AM – 12 noon
- Location: Convention Center, Halls A-C, Poster Section 33, Poster Board 2
- Presenter: Ann Silk, MD, MS, Medical Oncologist, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

The poster presentation will report preliminary data from the phase 1b CAPRA (CAVATAK and Pembrolizumab in Advanced Melanoma) study designed to evaluate the tolerability and anti-cancer activity of intralesionally injected CAVATAK in combination with the systemic administration of KEYTRUDA (pembrolizumab) in patients with unresectable melanoma.

The text of the abstract will be posted on the [AACR meeting website](#) and the Viralytics websites from 4:30 p.m. Eastern US time on Wednesday, March 1, 2017 (Thursday March 2, at 8.30am Sydney time). The poster presentation will be available on the [AACR meeting](#) and the Viralytics websites at the date and time of the presentation.

“We are pleased to have this opportunity to update CAVATAK’s progress in the clinic including two podium presentations in a clinical trials plenary session at this prestigious oncology conference,” stated Malcolm McColl, Viralytics Managing Director. “These combination studies of CAVATAK and checkpoint inhibitors will help us to determine the potential of CAVATAK to enhance the activity of this important new class of immunotherapeutic agents.”

---

<sup>2</sup> KEYTRUDA<sup>®</sup> is a trademark of Merck Sharp & Dohme Corp



**About Viralytics Ltd:**

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK<sup>®</sup>, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit [www.viralytics.com](http://www.viralytics.com).

**Enquiries:**

Dr Malcolm McColl  
Chief Executive Officer  
+61 2 9988 4000

Mr Robert Vickery  
Chief Financial Officer  
+61 2 9988 4000

Ms Jennifer Cook Williams  
Cook Williams Communications  
+1 360-668-3701  
[jennifer@cwcomm.org](mailto:jennifer@cwcomm.org)